Site icon OncologyTube

Considering Whether Sorafenib Is Tolerable In Combination With I-O In HCC

Andrew X. Zhu, MD, PhD Associate Professor, Department of Medicine, Harvard Medical School, Director, Liver Cancer Research, Medicine, Massachusetts General Hospital, Discusses Considering Whether Sorafenib Is Tolerable In Combination With I-O In HCC. At The 2019 Gastrointestinal Cancers Symposium In San Francisco, CA On Jan 17, 2019. http://obroncology.com

Exit mobile version